CDKN2A Alterations and Response to Immunotherapy in Solid Tumors

Volume: 27, Issue: 14, Pages: 4025 - 4035
Published: Jun 1, 2021
Abstract
Immune checkpoint inhibitors (ICI) have shown clinical benefit in many types of metastatic cancers with only a few predictive biomarkers identified so far. CDKN2A is commonly altered in human cancers, but prior studies have provided conflicting evidence regarding the association between CDKN2A genomic alterations (GA) and response to ICIs. Herein, we examined the impact of loss-of-function CDKN2A alterations on response and survival in patients...
Paper Details
Title
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Published Date
Jun 1, 2021
Volume
27
Issue
14
Pages
4025 - 4035
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.